Association of CSF apolipoprotein E, Abeta42 and cognition in Alzheimer's disease. (Q51960495)

19 April 2018

title

Association of CSF apolipoprotein E, Abeta42 and cognition in Alzheimer's disease. (English)

1 reference

19 April 2018

5

Vanmechelen E

1 reference

19 April 2018

Matthias Riemenschneider

1

object named as

Riemenschneider M

1 reference

19 April 2018

Nicola Lautenschlager

3

object named as

Lautenschlager N

1 reference

19 April 2018

author name string

Schmolke M

2

1 reference

19 April 2018

Vanderstichele H

4

1 reference

19 April 2018

Guder WG

6

1 reference

19 April 2018

Kurz A

7

1 reference

19 April 2018

publication date

1 March 2002

1 reference

19 April 2018

published in

Neurobiology of Aging

1 reference

19 April 2018

volume

23

1 reference

19 April 2018

issue

2

1 reference

19 April 2018

page(s)

205-211

1 reference

19 April 2018

Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Hydrogen peroxide mediates amyloid beta protein toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

1 reference

7 January 2021

Intraneuronal Abeta42 accumulation in human brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Apolipoprotein E type 4 allele and Alzheimer's disease: effect on age at onset and relative risk in different age groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Glial cytokines in Alzheimer's disease: Review and pathogenic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

beta-Amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Beta-amyloid-induced changes in cultured astrocytes parallel reactive astrocytosis associated with senile plaques in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probable Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Apolipoprotein E (apoE) levels in brains from Alzheimer disease patients and controls.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Tau protein and apolipoprotein E in CSF diagnostics of Alzheimer's disease: impact on non Alzheimer's dementia?

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Apolipoprotein E in cerebrospinal fluid in 85-year-old subjects. Relation to dementia, apolipoprotein E polymorphism, cerebral atrophy, and white matter lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Cerebrospinal fluid apo E and apo A-I concentrations in early- and late-onset Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Apolipoprotein E mRNA in the brains of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

High expression of apolipoprotein E mRNA in the brains with sporadic Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

Increased apolipoprotein E mRNA in the hippocampus in Alzheimer disease and in rats after entorhinal cortex lesioning

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2801%2900272-X

7 January 2021

10.1016/S0197-4580(01)00272-X

Identifiers

DOI

1 reference

19 April 2018

1 reference

19 April 2018